SGLT inhibitor raises ketoacidosis risk in type 1 diabetes

The addition of the SGLT-1 and -2 inhibitor sotagliflozin to usual insulin therapy can increase the proportion of patients with type 1 diabetes achieving a glycated haemoglobin level lower than 7.0%. However treatment with the SGLT inhibitor came with an increased risk of diabetic ketoacidosis, according to a phase 3 trial of 1,400 patients across 133 ...

Already a member?

Login to keep reading.

© 2021 the limbic